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ABSTRACT
Objective: Chemotherapy-induced nausea and vomiting
(CINV) is a signiﬁcant problem for cancer patients. Aprepi-
tant, a novel NK-1 receptor antagonist, is approved for use
with 5-HT3 antagonists and corticosteroids to prevent CINV
associated with highly emetogenic chemotherapy. Neverthe-
less, the cost-effectiveness of standard aprepitant use has not
been established.
Methods: We developed a Markov model to compare three
strategies for CINV: conventional treatment with a 5-HT3
antagonist and a corticosteroid, conventional treatment plus
aprepitant, and conventional treatment with aprepitant
added after the onset of CINV. Data from published clinical
trials provided probabilities and utilities for the model. Data
from the Centers for Medicare and Medicaid Services and the
Federal Supply Scale provided costs for medical resources
and medications utilized. Resource use data were based on a
randomized clinical trial and routine clinical practice. The
incremental cost-effectiveness ratio (ICER) for each aprepi-
tant strategy was calculated in US$ per healthy day equiva-
lent (HDE) and converted to dollars per quality-adjusted life-
year (QALY). Univariate and probabilistic sensitivity analy-
ses addressed uncertainty in model parameters.
Results: Adding aprepitant after CINV occurred cost $264
per HDE ($96,333/QALY). The three-drug strategy cost
$267/HDE with a 95% conﬁdence range of $248-$305/
HDE ($97,429/QALY; $90,396–$111,239/QALY). In uni-
variate analyses, the most inﬂuential factors on the ICER
were: the cost of aprepitant, the likelihood of delayed CINV
without aprepitant, the likelihood of acute CINV with/with-
out aprepitant, and the increase in HDE from avoiding
CINV.
Conclusions: Aprepitant provides modest incremental bene-
ﬁts compared with conventional management of CINV. Rou-
tine aprepitant use appears most cost-effective when the
likelihood of delayed CINV or the cost of rescue medications
is high.
Keywords: cost-effectiveness, health-care utilization, nausea
and vomiting.
Introduction
Patients  frequently  cite  nausea  and  vomiting  as  one
of the most distressing and debilitating side effects of
chemotherapy [1–6]. Chemotherapy-induced nausea
and vomiting (CINV) can be divided into acute (24 or
fewer hours after chemotherapy), delayed (more than
24 hours after chemotherapy) or anticipatory (before
chemotherapy) [7]. This distinction is made because
acute CINV is believed to be mediated through serot-
onin receptor stimulation while delayed CINV is
thought to involve multiple neurotransmitters, includ-
ing opioid and neurokinin receptors [8]. Chemothera-
peutic agents have variable emetogenic potential that is
affected by dose and method of administration [9–11].
For example, cisplatin, one of the most emetogenic
agents, has rates of acute vomiting approaching 100%
in the absence of anti-emetic therapy [12]. Adequate
control of CINV is essential to effectively delivery cis-
platin and other highly emetogenic chemotherapy.
Ondansetron was the ﬁrst 5-hydroxytryptamine3
(5-HT3) antagonist approved for use against CINV.
Several randomized clinical trials demonstrated the
superiority of ondansetron for control of acute CINV
when compared with metoclopramide and/or dexam-
ethasone containing regimens [13–18]. Other 5-HT3
antagonists, such as granisetron, dolasetron, and tro-
pisetron, are as efﬁcacious as ondansetron [19]. The
combination of a 5-HT3 antagonist plus corticosteroid
has emerged as conventional management for preven-
tion of CINV associated with highly emetogenic chem-
otherapy [20]. Even with conventional management,
approximately 20% to 30% of patients receiving cis-
platin experience acute CINV [21,22]. Moreover, this
regimen appears to provide limited beneﬁts for delayed
CINV, with 40% to 50% of patients continuing to
experience delayed CINV [23–26].
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Neurokinin-1 (NK-1) antagonists recently have
been introduced as a new class of drugs available to
prevent and treat CINV. These agents block the inter-
action of substance P, a neurotransmitter thought to
play an important role in the development of nausea
and vomiting, with the NK-1 receptor [27]. Aprepi-
tant, the ﬁrst commercially available NK-1 antagonist,
improves control of both acute CINV, when added to
a 5-HT3 antagonist and corticosteroid, and delayed
CINV, when combined with a corticosteroid [28–30].
The improved efﬁcacy of aprepitant persists over mul-
tiple cycles of cisplatin-based chemotherapy [31]. The
addition of aprepitant to the armamentarium of anti-
emetic agents has led to recent changes in treatment
guidelines for prevention of CINV. Revised 2005
National Comprehensive Cancer Network guidelines
for prevention of CINV now recommend the routine
addition of aprepitant to the standard combination of
a 5-HT3 antagonist with a corticosteroid when admin-
istering highly emetogenic chemotherapy [32].
The primary objective of this study is to determine
whether the additional costs associated with adding a
NK-1 inhibitor for the prevention of CINV are justi-
ﬁed by the additional efﬁcacy and improvement in
quality of life. The costs and beneﬁts of a 5HT-3 antag-
onist and corticosteroid, for the prevention of CINV
associated with highly emetogenic chemotherapy, were
compared with the following strategies: 1) a three-drug
regimen consisting of aprepitant, a 5HT-3 antagonist,
and a corticosteroid; or 2) a strategy adding aprepitant
to the conventional regimen only after CINV occurs
with a prior cycle of chemotherapy.
Methods
Decision Model
We developed a Markov model with a 28-day cycle
length to compare costs and clinical outcomes associ-
ated with each regimen in a hypothetical cohort of
patients receiving a chemotherapeutic regimen includ-
ing 70 mg/m2 or less of cisplatin. The structure of the
model is shown in Figure 1. A patient in the model
could experience one of four outcomes: 1) neither
acute nor delayed CINV; 2) acute CINV only; 3)
delayed CINV only; or 4) both acute and delayed
CINV. We utilized published data from a randomized
clinical trial by Hesketh et al. to establish probabilities
for each outcome (Table 1) [28]. Costs were calculated
from the payer perspective with results reported in
2005 US dollars. We modeled patient care costs and
outcomes over the time horizon from administration
Figure 1 The Markov model comparing costs
and clinical outcomes associated with each reg-
imen. CINV, chemotherapy-induced nausea and
vomiting.
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Table 1 Probabilities used in the model
Probability Base case Range
Standard regimen
Acute CINV 0.219 0.138–0.300
Delayed CINV-acute CINV 0.815 0.739–0.891
No acute CINV 0.781 0.700–0.862
Delayed CINV-no acute CINV 0.306 0.216–0.396
Three-drug regimen
Acute CINV 0.108 0.047–0.169
Delayed CINV-acute CINV 0.692 0.602–0.783
No acute CINV 0.892 0.831–0.953
Delayed CINV-no acute CINV 0.137 0.070–0.204
CINV, chemotherapy-induced nausea and vomiting.
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of the ﬁrst cycle of the cisplatin containing chemother-
apeutic regimen through a total of ﬁve cycles.
Treatment regimens were based on the approved
usage of aprepitant as deﬁned in the registration clin-
ical trials. The conventional treatment arm consisted
of ondansetron 32 mg IV and dexamethasone 20 mg
PO given on day 1 followed by dexamethasone 8 mg
PO twice daily on days 2 to 4. The three-drug regimen
consisted of ondansetron 32 mg IV, dexamethasone
12 mg PO and aprepitant 125 mg PO on day 1 fol-
lowed by aprepitant 80 mg PO and dexamethasone
8 mg PO once daily on days 2 to 3 then dexametha-
sone 8 mg PO on day 4 [28]. The third arm of the
model utilized conventional management until the
occurrence of acute or delayed CINV and switched to
the three-drug treatment regimen for all remaining
cycles. The probabilities used in the model and ranges
explored in univariate sensitivity analyses were
obtained  from  randomized  clinical  trial  data  and
are shown in Table 1 [28]. Probability ranges were
obtained by constructing 95% conﬁdence intervals for
proportions derived from the literature using normal
approximations to the binomial distribution [33].
Costs
Costs of care are shown in Table 2. The costs of clinic
and laboratory based resources were derived from year
2005 reimbursement data and physicians’ fee sched-
ules available from the Centers for Medicare and Med-
icaid Services (CMS) [34]. Medication costs were
obtained from the Federal Supply Scale (FSS) [35,36].
The cost of rescue treatment for CINV included a
clinic visit, comprehensive metabolic panel, and pre-
scription for 30 tablets of both metoclopramide 10 mg
and ativan 1 mg. It was assumed that drug delivery
costs were equal across treatment groups. The anti-
emetic medications under consideration are well toler-
ated and typically do not result in adverse events
requiring additional medical attention. In the probabi-
listic sensitivity analysis, all cost data were modeled as
normal distributions with the base-case value as the
mean. The difference between high and low CMS and
FSS values were used to approximate the standard
deviation [34,37,38].
Utilities for the Outcomes
Model utilities were measured in healthy day equiva-
lents (HDEs) and were obtained from a study by Dran-
itsaris and Leung using the Time Trade-Off (TTO)
method (Table 3) [39,40]. In this study, subjects were
asked how many days of “optimal health” they con-
sidered being equivalent to the time spent in various
health states including combinations of acute and
delayed CINV. Mean HDEs were used in the base-case
analysis. Incremental beneﬁt was converted to quality-
adjusted life-years (QALYs), by dividing the difference
in the mean HDEs for each treatment by 365 to esti-
mate the number of healthy year equivalents (HYEs)
gained [41]. When the TTO method is used to elicit
utilities, estimation of HYEs and QALYs utilize the
same assumptions and yield theoretically identical
results [42,43].
Sensitivity Analyses
Univariate sensitivity analyses were performed to
explore the impact of varying all probabilities, utilities,
and costs on the incremental cost-effectiveness of the
aprepitant management strategies. Probabilities and
utilities were varied over the ranges derived from their
95% conﬁdence intervals. Costs were varied according
to minimum and maximum allowable payments from
CMS reimbursement rates for physician and labora-
tory services and minimum and maximum medication
costs from the FSS [34].
A probabilistic sensitivity analysis was performed
to assess the robustness of the ﬁndings in the base case
and provide conﬁdence ranges for the incremental cost
and effectiveness of the treatment strategies. A Monte
Carlo simulation used 10,000 samples drawn from
Table 2 Estimated costs of care
Costs
Cost
($)
Range 
($)
Component costs
Aprepitant 125 mg tab 64.27 64.12–64.42
Aprepitant 80 mg tab 59.09 59.06–59.11
Ondansetron 32 mg IV 134.83 131.68–137.98
Dexamethasone 4 mg tab 0.08 0.06–0.11
Metoclopramide 10 mg tab 0.12 0.01–0.90
Ativan 1 mg tab 0.12 0.06–0.30
Clinic visit (CPT 99213) 36.18 32.10–59.49
Comprehensive metabolic
panel (CPT 80053)
14.77 11.74–14.77
Regimen costs
Standard regimen* 136.19 132.48–139.45
Three-drug regimen† 318.02 314.49–321.46
Rescue treatment‡ 58.15 45.87–110.26
*Standard regimen = Ondansetron 32 mg IV + (Dexamethasone 4 mg tab × 17).
†Three-drug Regimen = Aprepitant 125 mg tab + (Aprepitant 80 mg tab × 2) +
Ondansetron 32 mg IV + (Dexamethasone 4 mg tab × 9).
‡Rescue Treatment = Clinic visit, Comprehensive metabolic panel + (Metoclopra-
mide 10 mg tab × 30) + (Ativan 1 mg tab × 30).
Table 3 Utilities used in the model as measured in healthy day
equivalents (HDEs)
Health state HDEs
Range 
(95% CI)
Standard regimen
Both acute and delayed CINV 0.90 0.40–1.35
Acute CINV, no delayed CINV 3.00 2.55–3.40
No acute CINV, delayed CINV 1.55 1.10–2.05
No acute CINV or delayed CINV 4.30 3.95–4.65
Three-drug regimen
Both acute and delayed CINV 0.75 0.25–1.20
Acute CINV, no delayed CINV 3.00 2.55–3.45
No acute CINV, delayed CINV 1.40 0.90–1.90
No acute CINV or delayed CINV 4.25 3.85–4.70
CI, conﬁdence interval; CINV, chemotherapy-induced nausea and vomiting.
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distributions of probabilities, utilities, and costs. This
sampling procedure accounts for uncertainty in treat-
ment outcomes and was beyond the number of sam-
ples where convergence occurred. Expected values and
central 95% ranges were calculated for the incremen-
tal cost, effectiveness, and incremental cost-effective-
ness ratio (ICER). A willingness-to-pay threshold of
$50,000/QALY or less was used to deﬁne strategies
that provide cost-effective utilization of resources in
the US health-care system, as has been deﬁned by other
authors [44,45]. All analyses were conducted using
TreeAge Pro 2005 (Williamstown, MA, USA).
Results
During the 5 months of chemotherapy, the three-drug
treatment regimen provided patients with 2.47 addi-
tional HDEs at an incremental cost of $682 per patient
as compared with the standard treatment arm, and the
strategy of adding aprepitant only after CINV offered
an additional 1.24 HDEs at an incremental cost of
$289 per patient (Table 4). The resulting ICERs are
$267/HDE ($97,429/QALY) for the 3-drug strategy
and $264/HDE ($96,333/QALY) for the strategy of
adding aprepitant after development of CINV. Table 4
compares costs and beneﬁts for the treatment strate-
gies under consideration.
Univariate sensitivity analyses are displayed in a
tornado diagram (Fig. 2). In this diagram, each bar
represents the impact of uncertainty in an individual
variable on the ICER. No bars cross the $50,000/
QALY threshold, indicating that wide variation of the
estimates for cost, probability, and utility from those
chosen in our base case do not alter the results of our
analysis. Threshold values were calculated for each
variable but were meaningful only for the cost varia-
bles. The threshold value indicates the value of an indi-
vidual variable at which the use of aprepitant becomes
$50,000/QALY or less. At a cost of $96 for all apre-
pitant doses given during a cycle of chemotherapy,
the three-drug strategy is cost-effective. Similarly, the
ICER associated with adding aprepitant after the onset
of CINV is most sensitive to the cost of aprepitant. The
cost of rescue treatment also strongly inﬂuenced the
ICER. When rescue treatment costs more than $498,
the three-drug strategy becomes cost-effective. For
instance, if more than six doses of a 5-HT3 antagonist
are administered in rescue treatment, adding aprepi-
tant to prevent CINV is cost-effective.
The results of the probabilistic sensitivity analysis
were plotted as an incremental cost-effectiveness scat-
terplot (Fig. 3) to show the distribution of 10,000 tri-
als from the Monte Carlo simulation. Each trial point
provides a comparison of the incremental costs and
beneﬁts of three-drug management to conventional
care. For each comparison, parameters for both man-
agement strategies were simultaneously and randomly
sampled from the probability, cost, and outcome dis-
tributions to account for uncertainty in the base-case
parameter estimates. The points could fall in four
quadrants, the ﬁrst of which represents a scenario
where the three-drug management strategy is both
Table 4 Costs, healthy day equivalents (HDEs), quality-
adjusted life-years (QALYs), cost-effectiveness (CE) ratio, and
incremental cost-effectiveness ratio (ICER) of the treatment reg-
imens over ﬁve cycles of chemotherapy administration
Strategy
Cost
($) HDEs QALYs
CE ratio
($)
ICER 
($)
Standard regimen 711 11.93 0.033 21,545  —
Three-drug regimen 1393 14.40 0.040 34,825 97,429
Add aprepitant after CINV 1000 13.17 0.036 27,778 96,333
QALY = HDE/365; CE ratio = Cost/QALY.
CINV, chemotherapy-induced nausea and vomiting.
Figure 2 Tornado diagram of univariate analyses. CINV, chemotherapy-induced nausea and vomiting; QALY, quality-adjusted life-year.
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more costly and more effective than the standard reg-
imen. This quadrant contained 98.86% of the samples,
all of which had an ICER of greater than $50,000/
QALY. Quadrant II, where the three-drug strategy is
more costly but less effective, contained only 1.14% of
the samples. Quadrant III represents a situation where
the triple-drug strategy is both less costly and less
effective whereas quadrant IV represents a situation
where the triple-drug treatment strategy is less costly
and more effective. Neither quadrant III nor IV
contained points. From the probabilistic sensitivity
analysis, the ICER for the three-drug strategy was
$100,516/QALY (95% conﬁdence range $90,396/
QALY-$111,239/QALY).
Conclusions
Although aprepitant use for prevention of CINV
improves patient outcomes, the incremental beneﬁt of
the  three-drug  regimen  is  counterbalanced  by  the
cost associated with this new agent. Using HDEs as a
measure of quality of life, the addition of aprepitant
offered a moderate gain in HDEs. When translated
into QALYs, the ICER for aprepitant use exceeded
$50,000/QALY with both strategies tested in our
model and with wide variation in univariate and prob-
abilistic sensitivity analyses. Routine use of aprepitant
becomes cost-effective when the total cost of aprepi-
tant for each cycle of chemotherapy is less than $96
(approximately $32 per dose). Although these costs
are outside of the ranges used in the model, drug prices
are potentially subject to greater ﬂexibility than either
utilities or probabilities and could be adjusted to
achieve cost-effectiveness.
Assessing the cost-effectiveness of supportive care
measures in oncology is necessary to ensure equitable
allocation of resources given that the annual cost of
caring for patients with cancer in the United States
already exceeds $100bn [46]. Following the introduc-
tion of 5-HT3 antagonists for prevention of CINV, the
cost-effectiveness of these agents was studied exten-
sively. Several studies examining this issue found that
these agents are cost-effective for prevention of CINV
associated with both highly and moderately eme-
togenic chemotherapy [47–52]. These results likely
reﬂect the dramatically increased efﬁcacy of these
agents for prevention of acute CINV when compared
with the previous standard of care. Nevertheless, the
cost-effectiveness of 5-HT3 antagonists for prevention
of delayed CINV was recently assessed, and the use of
these agents does not appear to be cost-effective
beyond 24 hours after chemotherapy [53].
Economic evaluations provide important informa-
tion regarding allocation of scarce resources and the
desire to maximize economic efﬁciency [54]. A recent
study by Dranitsaris and Leung demonstrated how
decision analysis modeling can be used to estimate
cost-effective pricing of new pharmaceuticals before
they are introduced to the market [39]. This study
found that at a cost of $CAN6.60 per dose, aprepitant
would achieve economic efﬁciency relative to the
Canadian health-care system using a threshold of
$20,000/QALY to deﬁne “good value for money.” A
separate willingness-to-pay analysis conducted in Can-
ada, Spain, Italy, and Greece concluded that patients
with cancer are willing to pay from $8 to $63 (US$
based on year 2000 exchange rates) per day for a 20%
improvement in acute emesis and $9 to $50 per day
for a 30% improvement in delayed emesis. This wide
range represents signiﬁcant differences in patient val-
ues between countries even after adjusted for socioe-
conomic variables and previous history of emesis [12].
The ﬁndings of our study provide important infor-
mation regarding the role of the new NK-1 antagonist,
aprepitant, in the overall management of cancer
patients. Although the three-drug strategy provides
only modest beneﬁts for the prevention of CINV from
a cost-effectiveness standpoint, its improved efﬁcacy
despite its high cost may be justiﬁed in the proper set-
ting. In addition, the unit cost of aprepitant of approx-
imately $60 used in our study is similar to what cancer
patients in Western Europe were willing to pay for the
increased efﬁcacy of aprepitant, and the incremental
cost of $682 represents a small fraction of the total
cost of care for a patient receiving ﬁve cycles of chem-
otherapy. Moreover, the strategies analyzed in our
study represent only two possible means of utilizing
aprepitant to prevent CINV. It is likely that future
studies will help deﬁne the role of this new anti-emetic
agent for prevention of CINV. Our study indicates that
parameters most likely to affect the cost-effectiveness
of aprepitant include the cost of the medications, the
likelihood of experiencing delayed CINV without
treatment with an NK-1 antagonist, the likelihood of
Figure 3 Plot of the incremental cost versus incremental effectiveness
comparing the standard treatment and three-drug treatments.
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experiencing acute CINV with and without treatment,
and the beneﬁts patients attribute to not having CINV.
Although our base-case model yielded an ICER of
more than $50,000 per QALY, our sensitivity analyses
indicate that aprepitant may be cost-effective in clini-
cal environments where routine use of 5-HT3 antago-
nists as rescue medication is prevalent. In our model,
prophylaxis with aprepitant is cost-effective in situa-
tions where 3 days of postchemotherapy ondansetron
at a dose of 8 mg PO BID is used as rescue medication.
Although there is substantial evidence that the addi-
tion of 5-HT3 antagonists to corticosteroids following
the administration of highly emetogenic chemotherapy
does not effectively improve prevention of delayed
CINV, the use of 5-HT3 antagonists for rescue treat-
ment appears to be widespread [55–60]. A recent study
by Mertens et al. suggests that guidelines for the pre-
vention of delayed CINV are not widely followed. In
this study, only 25% of chemotherapy administrations
of moderately or highly emetogenic potential received
postchemotherapy corticosteroids. In contrast, 52% of
these chemotherapy administrations received post-
chemotherapy 5-HT3 antagonists. Among patients
receiving cisplatin, 23% received 5-HT3 antagonists
but none were prescribed concurrent dexamethasone
[60]. Thus, the use of aprepitant could be cost-effective
if the addition of this agent reduces ineffective pre-
scribing of 5-HT3 antagonists for the control of
delayed CINV.
Several limitations of this study must be addressed.
First, all probabilities and utilities used to populate the
model are estimates derived from the literature. Each
of these estimates carries inherent uncertainty. Possible
selection bias associated with utilizing data from a sin-
gle clinical trial as well as differences between the clin-
ical trial setting and actual clinical use may impact our
base-case effectiveness and resource use estimates by
either over or underestimating our base-case model
parameters. Nevertheless, both univariate and proba-
bilistic sensitivity analyses were performed to address
uncertainty in parameter estimates by exploring vari-
ability in each probability, cost, and outcome estimate.
These analyses and an alternative structure for the
model (aprepitant use after CINV occurs) addressed
parameter and structural uncertainty in the model. Of
note, utilities were speciﬁc to each strategy. Our results
are maintained even when a single set of utilities is
applied to all strategies. Second, the standard regimen
used in this study did not include combination therapy
for the prevention of delayed CINV. The combination
of metoclopramide and dexamethasone may represent
a more accepted strategy than dexamethasone alone
[61]. Nevertheless, the additional efﬁcacy of dexame-
thasone plus metoclopramide would bias the analysis
toward the standard arm being more effective, which
would make the aprepitant strategy appear even less
cost-effective. It is likely that the enhanced effective-
ness of dexamethasone plus metoclopramide was
contained in the ranges explored in our sensitivity
analyses. Third, it is possible that the costs of rescue
treatment were underestimated if patients who experi-
enced CINV required more aggressive intervention.
Nevertheless, a recent study by Ihbe-Hefﬁnger et al.
showed that only 14% of patients who experience
CINV required outpatient physician visits and only
0.5% required hospitalization [62]. Fourth, indirect
costs such as time lost in usual activities were not
considered. In the same study, 11.4% of patients with
CINV lost workdays or required extra help at home as
a result of their symptoms. The inclusion of such costs
might improve the cost-effectiveness of aprepitant.
Although our study modeled ondansetron at a dose
of 32 mg IV, several studies show that the dose of
ondansetron can be lowered to 8 mg rather than
32 mg without loss of efﬁcacy [63–65]. Additional
studies indicate that the oral route of administration is
equally as efﬁcacious as the intravenous route [66,67].
Although the total cost of CINV prevention would be
lowered by these adjustments, this change would affect
all strategies equally, and the ICER would therefore
remain unchanged. For example, at a cost of $33.71
for an 8-mg IV dose of ondansetron, the total cost of
the three-drug regimen over ﬁve cycles of chemother-
apy was $991 compared with $1393 for a 32-mg IV
dose of ondansetron. The resulting ICERs were $286/
HDE ($97,714/QALY) for the three-drug regimen and
$266/HDE ($97,000/QALY) for the strategy of adding
aprepitant after development of CINV when the cost
of an 8-mg IV dose was used in the model.
An additional issue is that costs derived from CMS
and FSS data may differ from other payer sources.
Nevertheless, Medicare reimbursement data may pro-
vide the best estimate of direct medical care costs,
because many public and private organizations use
Medicare reimbursement methodology to set reim-
bursement rates [34]. The FSS is a program utilized
by the Department of Veteran Affairs, Department of
Defense, Public Health Service, Coast Guard, and
Indian Health Service to obtain the best possible price
for pharmaceuticals by negotiating for equal to or
better than Most Favored Commercial Customer
prices [36]. Although these sources may result in an
underestimate of the true costs, this error would
inﬂuence all strategies. Finally, although $50,000/
QALY is a commonly applied metric of assessing the
cost-effectiveness of health-care interventions in the
United States [44,45], this is an arbitrary threshold.
The cost-effectiveness threshold of $50,000/QALY
was deﬁned in the 1970s based on the cost of provid-
ing treatment for patients with end-stage renal dis-
ease. The cost of this service is now thought to
exceed $120,000/QALY [68]. The results of our study
indicate that the routine use of aprepitant at a cost of
$97,429/QALY exceeds the accepted $50,000/QALY
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threshold but may be acceptable at a higher cost-
effectiveness threshold.
Despite these limitations, our study suggests that
the use of aprepitant for prevention of CINV associ-
ated with highly emetogenic chemotherapy provides
beneﬁts for preventing CINV at a current cost of the
three-drug regimen that exceeds the common thresh-
old for cost-effectiveness. Nevertheless, in clinical envi-
ronments, where the risk of delayed CINV is high or
the strategies for rescue treatment are costly, routine
aprepitant use may be cost-effective. Targeting high-
risk populations and understanding how actual CINV
prevention differs from guideline recommendations
will likely be necessary to identify other cost-effective
uses for aprepitant until the cost of the medication is
reduced.
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